Systematic study of cilostazol on secondary stroke prevention: A meta-analysis

European Journal of Medical Research

Volumn 18, Issue 1, 2013, Pages

  Qian, Yining ^a   Bi, Qi ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cilostazol; Ischemic stroke; Systematic reviews

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; PLACEBO; ANTITHROMBOCYTIC AGENT; TETRAZOLE DERIVATIVE;

ARTICLE; BLEEDING; BRAIN ISCHEMIA; DISEASE EXACERBATION; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; GASTROINTESTINAL DISEASE; HEART PALPITATION; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; META ANALYSIS; NEUROIMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; SYSTEMATIC REVIEW; TRANSCRANIAL DOPPLER; CLINICAL TRIAL (TOPIC); COMPLICATION; DISEASE COURSE; INCIDENCE; INTRACRANIAL ARTERIAL DISEASES; STROKE; TREATMENT OUTCOME; ARTERIAL WALL THICKNESS; DATA EXTRACTION; DOPPLER ECHOGRAPHY; HEADACHE; QUALITY CONTROL; STATISTICAL SIGNIFICANCE;

ASPIRIN; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; INCIDENCE; INTRACRANIAL ARTERIAL DISEASES; PLATELET AGGREGATION INHIBITORS; STROKE; TETRAZOLES; TREATMENT OUTCOME;

EID: 84889077149     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-18-53     Document Type: Article

References (35)

1. Early predictors of death and disability after acute cerebral ischemic event. Henon H, Godefroy O, Leys D, Mounier-Vehier F, Lucas C, Rondepierre P, Duhamel A, Pruvo J, Stroke 1995 26 392 398 10.1161/01.STR.26.3.392 7886712
2. Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. Harms H, Prass K, Meisel C, Klehmet J, Rogge W, Drenckhahn C, Göhler J, Bereswill S, Göbel U, Wernecke KD, PloS One 2008 3 2158 10.1371/journal.pone.0002158 18478129 (Pubitemid 352025150)
3. Collaborative overview of randomised trials of antiplatelet therapy.I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration, BMJ 1994 308 81 106 8298418
4. Risk factor profile and management of cerebrovascular patients in the REACH Registry. Rother J, Alberts MJ, Touze E, Mas JL, Hill MD, Michel P, Bhatt DL, Aichner FT, Goto S, Matsumoto M, Ohman EM, Okada Y, Uchiyama S, D'Agostino R, Hirsch AT, Wilson PW, Steg PG, Cerebrovasc Dis 2008 25 366 374 10.1159/000120687 18337635 (Pubitemid 351555862)
5. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. He J, Whelton PK, Vu B, Klag MJ, JAMA 1998 280 1930 1935 10.1001/jama.280.22.1930 9851479 (Pubitemid 28559811)
6. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M, Stroke 2003 34 2349 2354 10.1161/01.STR.0000090348.52943.A2 12958323 (Pubitemid 37221940)
7. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The antiphospholipid antibodies in stroke study group. Levine S, Brey R, Joseph C, Havstad S, Stroke 1992 23 29 1561671
8. Low-molecular-weight heparins and heparinoids in acute ischemic stroke a meta-analysis of randomized controlled trials. Bath PM, Iddenden R, Bath FJ, Stroke 2000 31 1770 1778 10.1161/01.STR.31.7.1770 10884486 (Pubitemid 30437536)
9. Clinical consequences of aspirin and clopidogrel resistance: an overview. Mijajlovic MD, Shulga O, Bloch S, Covickovic-Sternic N, Aleksic V, Bornstein NM, Acta Neurologica Scandinavica 2013 128 213 219 10.1111/ane.12111 23432706
10. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Kamal AK, Naqvi I, Husain MR, Khealani BA, Cochrane Database Syst Rev 2011 1 D008076 21249700
11. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, J Stroke Cerebrovasc Dis 2000 9 147 157 10.1053/jscd.2000.7216 24192020 (Pubitemid 30480490)
12. Evaluation of antidepressant and anxiolytic activity of phosphodiesterase 3 inhibitor-cilostazol. Patel DS, Anand IS, Bhatt PA, Indian J Psychol Med 2012 34 124 128 10.4103/0253-7176.101776 23162186
13. Experience from a multicentre stroke register: a preliminary report. Hatano S, Bull World Health Organ 1976 54 541 553 1088404 (Pubitemid 8114220)
14. Cilostazol in acute ischemic stroke treatment (CAIST trial): a randomized double-blind non-inferiority trial. Lee YS, Bae HJ, Kang DW, Lee SH, Yu K, Park JM, Cho YJ, Hong KS, Kim DE, Kwon SU, Lee KB, Rha JH, Koo J, Han MG, Lee SJ, Lee JH, Jung SW, Lee BC, Kim JS, Cerebrovasc Dis 2011 32 65 71 10.1159/000327036 21613787
15. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C, Lancet Neurol 2010 9 959 968 10.1016/S1474-4422(10)70198-8 20833591
16. Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. Guo JJ, Xu E, Lin QY, Zeng GL, Xie HF, Neurosci Bull 2009 25 383 390 10.1007/s12264-009-6192-2 19927175
17. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Li Z, Zhang W, Ding M, Gao X, Fan D, Zeng J, Wong K, Lu C, Xiao J, Yao C, Lancet Neurol 2008 7 494 499 10.1016/S1474-4422(08)70094-2 18456558
18. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, Kim JS, Stroke 2005 36 782 786 10.1161/01.STR.0000157667.06542.b7 15746463
19. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D, Stroke 2011 42 227 276 10.1161/STR.0b013e3181f7d043 20966421
20. Antiplatelet drugs in ischemic stroke prevention: from monotherapy to combined treatment. Urbano LA, Bogousslavsky J, Cerebrovasc Dis 2004 17 Suppl 1 74 80 14694284 (Pubitemid 38032525)
21. Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases. Symeonidis A, Kouraklis-Symeonidis A, Seimeni U, Galani A, Giannakoulas N, Fragopanagou E, Tiniakou M, Matsouka P, Zoumbos N, Am J Hematol 2002 71 24 32 10.1002/ajh.10150 12221670 (Pubitemid 34988582)
22. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Design, organization, and baseline results. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG, Stroke 1988 19 1203 1210 10.1161/01.STR.19.10.1203 3051529
23. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, Topol EJ, Am J Cardiol 2005 95 1218 1222 10.1016/j.amjcard.2005.01.049 15877994 (Pubitemid 40616424)
24. Use of cilostazol for secondary stroke prevention: an old dog with new tricks? Ansara AJ, Shiltz DL, Slavens JB, Ann Pharmacother 2012 46 394 402 10.1345/aph.1Q420 22353234
25. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Ikeda Y, Thromb Haemost 1999 82 435 438 10605734
26. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Goto S, Atherosclerosis Suppl 2005 6 3 11 (Pubitemid 43263084)
27. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J, Cardiovasc Drug Rev 2001 19 369 386 11830753 (Pubitemid 34260705)
28. Cilostazol as a unique antithrombotic agent. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F, Curr Pharm Des 2003 9 2289 2302 10.2174/1381612033453910 14529391 (Pubitemid 37236353)
29. Cilostazol improves symptomatic intracranial artery stenosis-evaluation of cerebral blood flow with single photon emission computed tomography. Kai Y, Watanabe M, Morioka M, Hirano T, Yano S, Ohmori Y, Kawano T, Hamada J, Kuratsu J, Surg Neurol International 2011 2 8
30. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Lugnier C, Pharmacol Ther 2006 109 366 398 10.1016/j.pharmthera.2005.07.003 16102838 (Pubitemid 43132818)
31. Cilostazol in the management of atherosclerosis. Sallustio F, Rotondo F, Di Legge S, Stanzione P, Curr Vasc Pharmacol 2010 8 363 372 10.2174/ 157016110791112331 20180773
32. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes. Shinoda-Tagawa T, Yamasaki Y, Yoshida S, Kajimoto Y, Tsujino T, Hakui N, Matsumoto M, Hori M, Diabetologia 2002 45 188 194 10.1007/s00125-001-0740-2 11935149 (Pubitemid 34208380)
33. Common carotid artery intima-media thickness and brain infarction: the Etude du Profil Genetique de l'Infarctus Cerebral (GENIC) case-control study. The GENIC Investigators. Touboul PJ, Elbaz A, Koller C, Lucas C, Adrai V, Chedru F, Amarenco P, Circulation 2000 102 313 318 10.1161/01.CIR.102.3.313 10899095 (Pubitemid 30457582)
34. Comparison between measures of atherosclerosis and risk of stroke: the Rotterdam study. Hollander M, Hak AE, Koudstaal PJ, Bots ML, Grobbee DE, Hofman A, Witteman JC, Breteler MM, Stroke 2003 34 2367 2372 10.1161/01.STR.0000091393. 32060.0E 12958327 (Pubitemid 37221943)
35. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK, J Vasc Surg 2003 38 710 713 10.1016/S0741-5214(03)01029-2 14560218 (Pubitemid 37254796)